Keywords: Crohn’s disease; JAK inhibitor; inflammatory bowel disease; pediatric; upadacitinib.
A pediatric patient with Crohn’s disease refractory to anti-tumor necrosis factor therapy, vedolizumab, ustekinumab, and 6-mercaptopurine achieved rapid clinical remission with upadacitinib. This is the first report of successful use of upadacitinib in pediatric inflammatory bowel disease.